What Happened
Federal health officials have directed the FDA to stop enforcing compounding restrictions against six peptides that have never been approved for human use: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. The policy, filed in the Federal Register as an enforcement-discretion notice, lets licensed compounding pharmacies prepare the substances without federal reprisal while the agency decides whether to write a formal rule.
Clinicians in western Pennsylvania, a region dense with academic medical centers and pharmacy schools, have responded bluntly. A clinical professor of pharmacy at a West Virginia university said the six compounds "do not have any large-scale studies demonstrating that they are safe, nor that they are effective," and noted that injecting an unstudied substance carries more risk than swallowing one. A Pittsburgh academic endocrinologist was equally direct: until rigorous human trial data exists, "these medications continue to be unsafe."
The Department of Health and Human Services says the goal is a regulated alternative to the gray market. The policy asks participating pharmacies to source ingredients only from FDA-registered facilities, verify purity and report adverse events. Officials stress that enforcement discretion is not approval, and that none of the six has been found safe or effective.
Who Is Affected
- Patients buying from clinics, telehealth prescribers or "research use only" storefronts now face a market that looks more legitimate without being better tested.
- Compounding pharmacies gain legal cover, plus sourcing and documentation duties that state pharmacy boards, not the FDA, have historically policed.
- Prescribers must decide whether to write for substances with no label, no approved indication and no standardized adverse-event reporting.
- Researchers inherit a noisier population of self-treated users.
Timeline
- 2023 — The FDA adds more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded, citing allergic reactions, kidney damage and tumor-growth concerns.
- April 2026 — The six peptides in the current policy are removed from that restricted list.
- July 2026 — An FDA advisory committee narrowly recommends allowing compounding. Agency scientists testify against it; reporting later describes a panel weighted toward peptide-industry supporters.
- October 28, 2026 — HHS publishes the enforcement-discretion policy.
- November 2026 — Clinicians go public with safety objections. No proposed rule has been issued.
What This Means for Researchers
The evidence gaps are specific and uneven. Per reporting on the advisory committee's review, one of the six has been tested in only a few very small human studies, with a possible immune reaction flagged; another has human data only from Russian trials and a theoretical bleeding signal; another carries a hypothetical cancer risk with prolonged exposure; several have no human data at all; one showed mixed results in mice. That is not one uniform "unproven" label — it is six different gaps calling for six different study designs.
How to Verify Your Peptides
Batch-level identity testing confirms the molecule is what the label says; purity testing catches truncated sequences and residual solvents; fill-weight checks catch underdosed vials. Our explainers cover how testing works, HPLC versus LC-MS and identity, purity and fill weight.
Safe Alternatives
Where an approved option exists, it remains the better-evidenced choice. Our references for semaglutide and tirzepatide summarize what trials actually showed, and the vendor directory lists suppliers that publish batch documentation. The full index is at peptides.
Sources
- Regulatory announcements: HHS enforcement-discretion policy for six compounded peptides (October 28, 2026); FDA advisory committee proceedings (July 2026); FDA restricted-substance list actions (2023, April 2026).
- Industry reports: clinician statements to regional press (November 6, 2026).